Lipoproteins in Diabetes Mellitus (eBook)

Alicia Jenkins, MBBS, MD, FRACP, FRCPUniversity of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Oklahoma City, OK, USAPeter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACCCGH Medical Center, Sterling, ILUniversity of Illinois College of Medicine, Clinical Family and Community Medicine, Peoria, ILMichigan State University College of Osteopathic Medicine, Clinical Medicine, East Lansing, MI, USATimothy J. Lyons, MD, FRCP University of Oklahoma Health Sciences Center, Section of Endocrinology and Diabetes, Harold Hamm Diabetes Center, Oklahoma City, OK, USA

Ch1: Laboratory Assessment of Lipoproteins in DiabetesDavid R. SullivanBarry Lewis Ch2: Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin Resistance DiabetesMichael CobblePatrick D. MizeEliot A. Brinton Ch3: Insulin Resistance and AtherosclerosisKamalpreet SinghVasudevan A. Raghavan Ch4: Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 DiabetesThomas D. Dayspring Ch5: Lipoprotein Metabolism and Alterations induced by insulin resistance and diabetesGerald H. TomkinDaphne Owens  Ch6: Production and Metabolism of Triglyceride-Rich Lipoproteins in both the Normal and Diabetic States                                                                                                                                                                       Angela PirilloGiuseppe D. NorataAlberico L. Catapano Ch7: Lipoprotein(a): Structure, Metabolism and PathophysiologyAlicia J. JenkinsKaram M. KostnerGerhard M. Kostner Ch8: Lipoprotein Glycation in Diabetes MellitusAlicia J. JenkinsRichard L. KleinAndrzej S. JanuszewskiCh9: Lipoprotein (LDL and  HDL) Oxidation in Diabetes MellitusMarielle KaplanMichael AviramTony Hayek Ch10: The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in DiabetesMaria F. Lopes-VirellaGabriel Virella Ch11: Lipid – Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of DiabetesNarin OsmanPeter J. Little Ch12: Tools for Assessing Lipoprotein Metabolism in Diabetes MellitusRichard L. Klein Ch13: Endothelial Dysfunction and Dyslipidaemia in Type 2 Diabetes: Pathogenesis, Significance and TherapySandra J. HamiltonGerald F. Watts Ch14: Lipoproteins and Diabetic NephropathyVille-Petteri MäkinenNina TolonenPer-Henrik Groop Ch15: Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic RetinopathyMingyuan WuTimothy J. Lyons Ch16: Effects of Lifestyle (Diet, Plant Sterols, Excercise) and Glycemic Control on Lipoporteins in Diabetes    Peter Clifton Ch17: About Randomised Clinical Trials Related to Lipoproteins in Diabetes MellitusAnthony KeechAlicia J. JenkinsVal Gebski Ch18: Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsSeth S. MartinParag H. JoshiSteven R. Jones Ch19: The PPAR System in DiabetesJean Claude AnsquerChristelle Foucher Ch20: Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsEliot A. Brinton Ch21: Niacin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Diabetic PatientsHenry A. TranArthur Z. SchwartzbardJames A. Underberg Ch22: Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes MellitusHarold Bays Ch23: Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes                                 Peter J. LittleAlan ChaitAndrzej S. JanuszewskiAlex BobikDavid O’NealAlicia J. Jenkins